Figure 1.
Antibiotic exposures and CMV reactivation. Antibiotic exposures by day +14 (A) and day +100 (B). (C) Heat map showing antibiotic coexposures, with the color gradient representing the χ2 statistic. (D) Patients exposed to vancomycin experienced a higher rate of CMV reactivation. Ceph3+, third-generation or higher cephalosporins; Clinda, clindamycin; FQN, fluoroquinolones; Metro, metronidazole; Pip-Tazo: piperacillin-tazobactam; Vanc, vancomycin.

Antibiotic exposures and CMV reactivation. Antibiotic exposures by day +14 (A) and day +100 (B). (C) Heat map showing antibiotic coexposures, with the color gradient representing the χ2 statistic. (D) Patients exposed to vancomycin experienced a higher rate of CMV reactivation. Ceph3+, third-generation or higher cephalosporins; Clinda, clindamycin; FQN, fluoroquinolones; Metro, metronidazole; Pip-Tazo: piperacillin-tazobactam; Vanc, vancomycin.

Close Modal

or Create an Account

Close Modal
Close Modal